About OrbiMed Partners
OrbiMed Partners is a venture capital firm based in New York, NY. Since March 2010 it has filed Form D notices for 22 funds and seven related vehicles. The largest, OrbiMed Partners, Ltd., reported $2.61B raised from 779 investors.
Funds
OrbiMed Partners has 22 funds on file with the SEC, plus seven feeder, opportunity or co-investment vehicles. The funds have reported $11.74B raised.
Funds
22
plus 7 related vehicles
Raised
$11.74B
across these funds
Largest fund
$2.61B
OrbiMed Partners, Ltd.
Latest fund
OrbiMed Asia Partners VI, L.P.
filed Sep 29, 2025
Funds (SEC Form D)
| Fund | First filed | Amount raised | Target | Investors |
|---|---|---|---|---|
| OrbiMed Asia Partners VI, L.P.Private equity fund · 3(c)(7) · Form D/A ↗ | Sep 29, 2025 | $1,045,599,648Sep 2025: $0 May 2026: $533.9M Oct 2026: $1.04B | $1,045,599,648 | 72 |
| OrbiMed Asia Partners V, L.P.Private equity fund · 3(c)(7) · Form D/A ↗ | Apr 28, 2022 | $651,872,014Apr 2022: $0 Nov 2022: $651.8M | $1,100,000,000 | 68 |
| OrbiMed Private Investments IX, LPPrivate equity fund · 3(c)(7) · Form D/A ↗ | Apr 28, 2022 | $1,849,550,000Apr 2022: $0 Apr 2023: $1.84B | $1,900,000,000 | 141 |
| OrbiMed Private Investments VIII, LPPrivate equity fund · 3(c)(7) · Form D ↗ | Aug 27, 2020 | None yet | $1,400,000,000 | — |
| OrbiMed Genesis Fund, Ltd.Hedge fund · 3(c)(7) · Form D/A ↗ | Apr 14, 2020 | $145,947,234Apr 2020: $300K Apr 2021: $29.3M Apr 2022: $100.5M Apr 2023: $125.5M Apr 2024: $134.7M Apr 2025: $134.8M Apr 2026: $145.9M | Not set | 20 |
| OrbiMed New Horizons Fund, Ltd.Hedge fund · 3(c)(7) · Form D/A ↗ | Apr 14, 2020 | $86,691,450Apr 2020: $300K Apr 2021: $70.6M Apr 2022: $86.6M | Not set | 29 |
| OrbiMed New Horizons Fund, L.P.Hedge fund · 3(c)(7) · Form D/A ↗ | Apr 14, 2020 | $61,575,000Apr 2020: $25.3M Apr 2021: $47.3M Apr 2022: $60.2M Apr 2023: $61.5M | Not set | 55 |
| OrbiMed Asia Partners IV, L.P.Private equity fund · 3(c)(7) · Form D/A ↗ | Mar 5, 2020 | $486,882,011Mar 2020: $0 Sep 2020: $486.8M | $750,000,000 | 86 |
| OrbiMed Genesis Fund, L.P.Hedge fund · 3(c)(7) · Form D/A ↗ | Dec 12, 2019 | $353,340,923Dec 2019: $50.1M Dec 2020: $59.2M Dec 2021: $184.1M Dec 2022: $265.4M Dec 2023: $274.9M Dec 2024: $338.3M Dec 2025: $353.3M | Not set | 107 |
| OrbiMed Private Investments VII, LPPrivate equity fund · 3(c)(7) · Form D ↗ | Jan 30, 2018 | None yet | $1,000,000,000 | — |
| OrbiMed Asia Partners III, L.P.Private equity fund · 3(c)(7) · Form D/A ↗ | Feb 27, 2017 | $539,960,000Feb 2017: $0 Jun 2017: $431.5M Sep 2017: $539.9M | $539,960,000 | 97 |
| OrbiMed Israel Partners II, L.P.Private equity fund · 3(c)(7) · Form D ↗ | Dec 14, 2015 | None yet | $300,000,000 | — |
| OrbiMed Private Investments VI, LPPrivate equity fund · 3(c)(7) · Form D ↗ | Sep 15, 2015 | None yet | $950,000,000 | — |
| OrbiMed Global Healthcare Fund, L.P.Hedge fund · 3(c)(7) · Form D/A ↗ | Jul 14, 2014 | $113,350,000Jul 2014: $6.0M Jul 2015: $11.2M Jul 2016: $113.3M | Not set | 10 |
| OrbiMed Global Healthcare Associates Fund, L.P.Hedge fund · 3(c)(7) · Form D/A ↗ | Feb 19, 2014 | $17,150,000Feb 2014: $600K Feb 2015: $17.1M | Not set | 7 |
| OrbiMed Private Investments V, LPPrivate equity fund · 3(c)(7) · Form D ↗ | Nov 5, 2013 | $699,500,000 | $700,000,000 | 66 |
| OrbiMed Global Healthcare Fund, Ltd.Hedge fund · 3(c)(7) · Form D/A ↗ | Oct 15, 2013 | $988,150,000Oct 2013: $160.0M Jul 2015: $553.7M Jul 2016: $972.3M Jul 2017: $982.9M Jul 2019: $988.1M | Not set | 11 |
| OrbiMed Asia Partners II, LPVenture capital fund · 3(c)(7) · Form D ↗ | Aug 15, 2013 | None yet | $300,000,000 | — |
| OrbiMed Israel Partners Limited PartnershipVenture capital fund · 3(c)(7) · Form D ↗ | Apr 18, 2011 | $190,375,000 | Not set | 50 |
| OrbiMed Partners, Ltd.Hedge fund · 3(c)(7) · Form D/A ↗ | Mar 12, 2010 | $2,611,956,097Mar 2010: $132.6M Mar 2011: $156.0M Mar 2012: $693.6M Mar 2013: $1.03B Jul 2013: $1.14B Jul 2014: $1.54B Jul 2015: $2.02B Jul 2016: $2.37B Jul 2017: $2.44B Jul 2018: $2.50B Jul 2019: $2.51B Jul 2020: $2.52B Jul 2021: $2.60B Jul 2022: $2.61B | Not set | 779 |
| OrbiMed Partners II, L.P.Hedge fund · 3(c)(7) · Form D/A ↗ | Mar 12, 2010 | $1,779,469,650Mar 2010: $215.5M Mar 2011: $236.1M Mar 2012: $446.0M Mar 2013: $640.1M Jul 2013: $836.6M Jul 2014: $1.14B Jul 2015: $1.34B Jul 2016: $1.56B Jul 2017: $1.64B Jul 2018: $1.71B Jul 2019: $1.73B Jul 2020: $1.74B Jul 2021: $1.77B Jul 2022: $1.77B Jul 2023: $1.77B | Not set | 880 |
| OrbiMed Partners, L.P.Hedge fund · 3(c)(1) · Form D/A ↗ | Mar 12, 2010 | $128,115,033Mar 2010: $63.6M Mar 2011: $64.6M Mar 2012: $110.6M Mar 2013: $111.7M Jul 2013: $112.6M Jul 2014: $117.9M Jul 2015: $124.5M Jul 2016: $127.8M Jul 2017: $128.1M | Not set | 130 |
Amounts and investor counts come from each fund's latest Form D or amendment; the dated lines under an amount show what earlier filings reported. "Not set" means the fund did not give a target. Form D does not report returns.
Feeder, opportunity and co-investment vehicles (7)
| Vehicle | Kind | First filed | Amount raised | Investors | Filing |
|---|---|---|---|---|---|
| OrbiMed Private Investments X, LP | Co-investment vehicle | Sep 29, 2025 | $1,921,099,472 | 131 | Form D ↗ |
| OrbiMed RCO V Offshore Feeder, LP | Feeder or parallel fund | Nov 14, 2024 | $1,243,525,000 | 31 | Form D ↗ |
| OrbiMed Royalty & Credit Opportunities V, LP | Opportunity fund | Nov 14, 2024 | $1,243,525,000 | 52 | Form D ↗ |
| OrbiMed RCO IV Offshore Feeder, LP | Feeder or parallel fund | Jul 14, 2022 | $344,450,400 | 18 | Form D ↗ |
| OrbiMed Royalty & Credit Opportunities IV, LP | Opportunity fund | Apr 28, 2022 | $1,153,124,600 | 113 | Form D ↗ |
| OrbiMed Royalty & Credit Opportunities III, LP | Opportunity fund | Jan 29, 2019 | $889,835,000 | 69 | Form D ↗ |
| OrbiMed Royalty Opportunities II, LP | Opportunity fund | Feb 2, 2015 | $900,000,000 | 83 | Form D ↗ |
These vehicles usually hold a single investment or a small group of them. Their filings do not name the companies they hold.
Portfolio Companies
Companies where a OrbiMed Partners partner sits on the board, according to the company's own Form D. A board seat usually comes with an investment, but Form D does not list investors.
| Company | Location | OrbiMed Partners director | On the board | Latest raise |
|---|---|---|---|---|
| FORE US Bio Inc. | Philadelphia, PA | Erez Chimovits | 2023–2026 | $70.4M ↗Apr 2025 |
| Capstan Therapeutics, Inc. | San Diego, CA | Erez Chimovits | 2024 | $62.9M ↗Nov 2021 |
| ImmPACT Bio USA Inc. | West Hills, CA | Erez Chimovits | 2020–2024 | $139.8M ↗Jan 2022 |
| Vanqua Bio, Inc. | Chicago, IL | Mona Ashiya | 2019–2024 | $44.9M ↗Feb 2024 |
| ADARx Pharmaceuticals, Inc.Now public (ADRX) | San Diego, CA | Erez Chimovits | 2020–2023 | $200.0M ↗Aug 2023 |
People
Partners and officers named on OrbiMed Partners's fund filings.
SB
Sven Borho
Executive officer, director and promoter
On the filings for 26 funds.
WN
W. Neild
Executive officer, director and promoter
On the filings for 24 funds.
GH
Geoffrey Hsu
Executive officer and promoter
On the filings for 18 funds.
SI
Samuel Isaly
Executive officer, director and promoter
On the filings for 13 funds.
CS
C. Stevens
Executive officer
On the filings for 12 funds.
MS
Michael Sheffery
Executive officer and promoter
On the filings for 3 funds.
MA
AN
Anat Naschitz
Executive officer
On the filings for 2 funds.
EC
ND
Nissim Darvish
Executive officer
On the filings for 2 funds.
ES
Evan Sotiriou
Director
On the filings for 1 fund.
GC
Graham Collis
Director
On the filings for 1 fund.
Sources
- SECEvery Form D filing behind this page is linked in the tables above.